Astrocytoma pathophysiology

Revision as of 12:57, 17 August 2015 by Jyostna Chouturi (talk | contribs)
Jump to navigation Jump to search

Astrocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Astrocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Astrocytoma pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Astrocytoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Astrocytoma pathophysiology

CDC on Astrocytoma pathophysiology

Astrocytoma pathophysiology in the news

Blogs on Astrocytoma pathophysiology

Directions to Hospitals Treating Astrocytoma

Risk calculators and risk factors for Astrocytoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shivali Marketkar, M.B.B.S. [2]

Pathophysiology

Overview

Well-differentiated astrocytomas constitute about 25 to 30% of cerebral gliomas. They have a predilection for the cerebrum, cerebellum, hypothalamus, pons, and optic nerve and chiasm. Although astrocytomas have many different histological characteristics, the most common type is the well-differentiated fibrillary astrocytoma. These tumors express glial fibrillary acidic protein (GFAP), which possibly functions as a tumor suppressor[1], and is a useful diagnostic marker in a tissue biopsy. [2]

Grading

Astrocytomas have great variation in their presentation. The World Health Organization acknowledges the following grading system for astrocytomas:

  • Grade 1pilocytic astrocytoma - primarily pediatric tumor, with median age at diagnosis of 12
  • Grade 2 — diffuse astrocytoma
  • Grade 3 — anaplastic (malignant) astrocytoma
  • Grade 4glioblastoma multiforme (most common)

In addition to these four tumor grades, astrocytomas may combine with oligodendrocytes to produce oligoastrocytoma. Unique astrocytoma variants have also been known to exist.

Gross Pathology

A gross specimen of gemistocytic astrocytoma

Microscopic Pathology

Histologic diagnosis with tissue biopsy will normally reveal an infiltrative character suggestive of the slow growing nature of the tumor. The tumor may be cavitating, pseudocyst-forming, or noncavitating. Appearance is usually white-gray, firm, and almost indistinguishable from normal white matter.

The WHO has given a four point scale depending on the histologic grade of the tumor (see below). This article focuses on the well-differentiated (Grade 2) astrocytoma and Anaplastic(grade 3) astrocytoma. For grade 1 and 4 astrocytomas, see respective article headings:

Video

{{#ev:youtube|O0b4zyDQcyI}}


References

  1. M Toda; et al. (1994). "Cell growth suppression of astrocytoma C6 cells by glial fibrillary acidic protein cDNA transfection". Journal of Neurochemistry. 63 (5): 1975–1978. PMID 7931355.
  2. JHN Deck; et al. (1978). "The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors". Acta Neuropathologica. Springer Berlin / Heidelberg. 42 (3): 183–190. doi:10.1007/BF00690355.

Template:Nervous tissue tumors de:Astrozytom nl:Astrocytoom

Template:WikiDoc Sources